Skip to main content
. 2025 Nov 24;14(23):8334. doi: 10.3390/jcm14238334
AA Arachidonic Acid
ACC American College of Cardiology
ACS Acute Coronary Syndrome
AGE Advanced Glycation End products
AHA American Heart Association
ASCVD Atherosclerotic Cardiovascular Disease
BMI Body Mass Index
CAD Coronary Artery Disease
CABG Coronary Artery Bypass Graft
CCS Chronic Coronary Syndrome
CETP Cholesteryl Ester Transfer Protein
CI Confidence Interval
CPK-MB Creatine Kinase-Myocardial brain fraction
CV Cardiovascular
CVD Cardiovascular Disease
DES Drug Eluting Stent
EAS European Atherosclerosis Society
eLDL-TG Estimating Low-Density Lipoprotein-Triglycerides
EPA Eicosapentaenoic Acid
ESC European Society of Cardiology
FFAs Free Fatty Acids
FPG Fasting Plasma Glucose
GDMT Guideline Directed Medical Therapy
GISE Italian Society of Interventional Cardiology
HbA1c Glycated Hemoglobin
HDL High-Density Lipoprotein
HeFH Heterozygous familial hypercholesterolemia
HMG Co-A Hydroxymethylglutaryl-CoA
HoFH Homozygous Familial Hypercholesterolemia
HR Hazard Ratio
Hs-CRP High-sensitivity C-Reactive Protein
ICAM-1 Intercellular Adhesion Molecule-1
IDL Intermediate-Density Lipoprotein
IL Interleukin
IPE Icosapent Ethyl
IQR Interquartile range
IS Infarct Size
IVUS Intravascular Ultrasound
LDE-MTX Lipid Nanoemulsion-Methotrexate
LDL-C Low-Density Lipoprotein
LDL-R Low-Density Lipoprotein Receptors
LLT Lipid-Lowering Therapy
LPL Lipoprotein Lipase
Lp(a) Lipoprotein A
LVR Left Ventricular Remodeling
MACE Major Adverse Cardiovascular Event
MCP Monocyte Chemotactic Protein
MI Myocardial Infarction
MMP Matrix Metalloproteinases
MTX Methotrexate
NADH/NADPH Nicotinamide adenine dinucleotide reduced form/Nicotinamide adenine dinucleotide phosphate reduced
NET Neutrophil Extracellular Traps
NIRS Near-Infrared Spectroscopy
NLRP3 NACHT, LRR and PYD domains-containing protein 3
NPC1L1 Niemann-Pick C1-like protein 1
NSTEMI No-ST-up Elevation Myocardial Infarction
NYHA New York Heart Association
OCT Optical Coherence Tomography
OGTT Oral Glucose Tolerance Test
OMT Optimal Medical Therapy
OR Odds Ratio
PAI Plasma fibrinogen Activator Inhibitor
PCI Percutaneous Coronary Intervention
PCSK9-i Proprotein Convertase Subtilisin/Kexin type 9 Inhibitor
PUFA Polyunsaturated Fatty Acids
ROS Reactive Oxygen Species
RR Relative Risk
SIL2r Soluble IL-2 receptor
SMCs Smooth Muscle Cells
STEMI ST-up Elevation Myocardial Infarction
T2DM Type 2 Diabetes Mellitus
TG Triglycerides
TGRLs Triglyceride-Rich Lipoproteins
TNF Tumor Necrosis Factor
TyG Triglyceride-Glucose
VCAM-1 Vascular Cell Adhesion Molecule-1
VLDL Very-Low-Density Lipoprotein